title: Comparing efficacy of BCG/lactoferrin primary vaccination versus booster regimen.
abstract: Lactoferrin is an iron binding glycoprotein possessing multiple immune modulatory activities, including ability to affect macrophage cytokine production, promote maturation of T- and B-lymphocyte and immature dendritic cells, and enhance the ability of macrophages and dendritic cells to stimulate antigen-specific T-cells. These characteristics of lactoferrin suggested that it could function as an effective adjuvant enhance efficacy of the BCG, the current vaccine for tuberculosis disease. Admix of lactoferrin to the BCG vaccine promoted host protective responses that surpasses activity of the BCG vaccine alone as determined by decreasing pulmonary pathology upon challenge with virulent Mycobacterium tuberculosis (MTB). This study builds on previous reports by examining the effectiveness of the lactoferrin adjuvant comparing primary vaccination versus an immunization schedule with a booster administered at 8 weeks. BCG/lactoferrin vaccinating, given once or twice, demonstrated an improvement in pulmonary disease compared to both the BCG vaccinated and non-immunized groups. The splenic recall profiles showed a difference in cytokine production induced by mycobacterial antigen from splenocytes isolated from mice immunized with BCG/lactoferrin once or twice. Production of IL-17 is increased in the BCG/lactoferrin 2× group compared to the primary vaccinated group. Both BCG/lactoferrin vaccinated group exhibited increase production of IFN-γ compared to the non-immunized group and decreased production of IL-10 compared to the group vaccinated with only BCG. This study illustrates that the adjuvant activity of lactoferrin to enhance BCG efficacy occurs whether the vaccination regimen is a single delivery or combined with a booster, leading to enhanced host protection and decreased disease manifestation.
authors.affiliation: Department of Pathology and Laboratory Medicine, University of Texas-Houston Medical School, 6431 Fannin, MSB 2.214, Houston, TX 77030, USA.
authors.forename: Shen-An
authors.initials: SA
authors.lastname: Hwang
authors.forename: Kerry J
authors.initials: KJ
authors.lastname: Welsh
authors.forename: Sydney
authors.initials: S
authors.lastname: Boyd
authors.forename: Marian L
authors.initials: ML
authors.lastname: Kruzel
authors.forename: Jeffrey K
authors.initials: JK
authors.lastname: Actor
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D001500:BCG Vaccine / Q000276:immunology*; D058491:Bacterial Load; D015169:Colony Count, Microbial; D016207:Cytokines / Q000096:biosynthesis; D004195:Disease Models, Animal; D005260:Female; D007117:Immunization, Secondary; D007781:Lactoferrin / Q000276:immunology*; D008099:Liver / Q000382:microbiology; D008168:Lung / Q000382:microbiology / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D013154:Spleen / Q000276:immunology; D014397:Tuberculosis, Pulmonary / Q000276:immunology / Q000382:microbiology / Q000473:pathology / Q000517:prevention & control*; D014611:Vaccination / Q000379:methods
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D016207:Cytokines; D007781:Lactoferrin
references.citation: Vaccine. 2009 May 18;27(23):3026-34
references.pmid: 19428915
references.citation: Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):7-12
references.pmid: 15687021
references.citation: Cell. 2009 Jan 9;136(1):17-9
references.pmid: 19135882
references.citation: J Immunol. 2007 Mar 1;178(5):2661-5
references.pmid: 17312107
references.citation: J Infect Dis. 2002 Dec 15;186(12):1808-14
references.pmid: 12447767
references.citation: Eur J Immunol. 2010 Aug;40(8):2200-10
references.pmid: 20518032
references.citation: Expert Opin Biol Ther. 2007 Nov;7(11):1665-77
references.pmid: 17961090
references.citation: Curr Pharm Des. 2009;15(17):1956-73
references.pmid: 19519436
references.citation: Med Microbiol Immunol. 2007 Sep;196(3):171-80
references.pmid: 17377816
references.citation: Tuberculosis (Edinb). 2009 Dec;89 Suppl 1:S18-25
references.pmid: 20006299
references.citation: J Immunol. 2007 Mar 15;178(6):3786-96
references.pmid: 17339477
references.citation: Immunology. 1995 Sep;86(1):122-7
references.pmid: 7590872
references.citation: J Clin Invest. 2009 May;119(5):1167-77
references.pmid: 19381021
references.citation: PLoS Pathog. 2009 Apr;5(4):e1000392
references.pmid: 19381260
references.citation: Infect Immun. 2006 Jul;74(7):4295-309
references.pmid: 16790804
references.citation: Comp Med. 2008 Aug;58(4):324-40
references.pmid: 18724774
references.citation: FASEB J. 2008 Aug;22(8):2747-57
references.pmid: 18364398
references.citation: Biochem Cell Biol. 2006 Jun;84(3):303-11
references.pmid: 16936801
references.citation: J Cell Biochem. 2000 Sep 14;79(4):583-93
references.pmid: 10996849
references.citation: Paediatr Respir Rev. 2011 Mar;12(1):46-51
references.pmid: 21172675
references.citation: Clin Dev Immunol. 2011;2011:307631
references.pmid: 21197439
references.citation: J Exp Med. 2010 Aug 2;207(8):1609-16
references.pmid: 20624887
references.citation: Eur J Immunol. 2008 Mar;38(3):695-705
references.pmid: 18266274
references.citation: Tuberc Res Treat. 2011;2011:835410
references.pmid: 22567270
references.citation: Vaccine. 2007 Sep 17;25(37-38):6730-43
references.pmid: 17698261
references.citation: Eur J Immunol. 2000 Dec;30(12):3689-98
references.pmid: 11169412
references.citation: Epidemiol Rev. 1993;15(2):265-302
references.pmid: 8174658
references.citation: Cell Microbiol. 2010 Mar;12(3):301-9
references.pmid: 20039878
references.citation: Biochimie. 2009 Jan;91(1):76-85
references.pmid: 18486627
references.citation: Cell Immunol. 2006 Jul;242(1):23-30
references.pmid: 17034774
references.citation: Nat Rev Microbiol. 2005 Aug;3(8):656-62
references.pmid: 16012514
references.citation: Biochim Biophys Acta. 1998 Apr 24;1402(3):277-87
references.pmid: 9606986
references.citation: Infect Immun. 2005 Mar;73(3):1744-53
references.pmid: 15731075
references.citation: Tuberculosis (Edinb). 2009 Dec;89 Suppl 1:S49-54
references.pmid: 20006305
references.citation: Anticancer Res. 2002 May-Jun;22(3):1897-901
references.pmid: 12168890
references.citation: Vaccine. 2010 Oct 8;28(43):6945-50
references.pmid: 20692219
references.citation: Eur J Immunol. 2003 Oct;33(10):2676-86
references.pmid: 14515251
references.citation: Int Immunol. 2009 Oct;21(10):1185-97
references.pmid: 19692539
references.citation: Yale J Biol Med. 2010 Dec;83(4):209-15
references.pmid: 21165340
references.citation: Immunity. 2008 Apr;28(4):454-67
references.pmid: 18400188
references.citation: Comp Immunol Microbiol Infect Dis. 2008 Mar;31(2-3):77-100
references.pmid: 17764740
references.citation: J Immunol. 2004 Oct 1;173(7):4590-7
references.pmid: 15383593
references.citation: Cytokine Growth Factor Rev. 2010 Dec;21(6):455-62
references.pmid: 21075039